Quick Takeaways
- This page summarizes Roderick de Greef's Form 4 filing for BIOLIFE SOLUTIONS INC (BLFS).
- 5 reported transactions and 0 derivative rows are listed below.
- Filing timestamp: 26 Feb 2026, 17:55.
Roderick de Greef - 24 Feb 2026 Form 4 Insider Report for BIOLIFE SOLUTIONS INC (BLFS)
- Signature
- /s/ Roderick de Greef
- Issuer symbol
- BLFS
- Transactions as of
- 24 Feb 2026
- Net transactions value
- -$3,469,889
- Form type
- 4
- Filing time
- 26 Feb 2026, 17:55:41 UTC
- Previous filing
- 13 Nov 2025
- Next filing
- 23 Mar 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Roderick de Greef filed Form 4 for BIOLIFE SOLUTIONS INC (BLFS) on 26 Feb 2026."
What Changed
- Previous filing in this sequence was filed on 13 Nov 2025.
- Current net transaction value: -$3,469,889.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Official SEC Source
Reporting Owners (1)
| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| DE GREEF RODERICK | President and CEO, Director | 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL | /s/ Roderick de Greef | 26 Feb 2026 | 0001241181 |
Transactions Table
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BLFS | Common Stock | Award | +118,730 | +30% | 508,728 | 24 Feb 2026 | Direct | F1 | ||
| transaction | BLFS | Common Stock | Award | +170,291 | +33% | 679,019 | 24 Feb 2026 | Direct | F2 | ||
| transaction | BLFS | Common Stock | Tax liability | $1,517,776 | -67,010 | -9.9% | $22.65 | 612,009 | 24 Feb 2026 | Direct | F3 |
| transaction | BLFS | Common Stock | Award | +219,024 | +36% | 831,033 | 24 Feb 2026 | Direct | F4 | ||
| transaction | BLFS | Common Stock | Tax liability | $1,952,113 | -86,186 | -10% | $22.65 | 744,847 | 24 Feb 2026 | Direct | F5 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2026 compensation. |
| F2 | The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant, the restricted stock vested as to approximately 156% of the number of shares granted based on the registrant's total shareholder return during the period beginning on January 1, 2024 through December 31, 2025 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| F3 | Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award. |
| F4 | The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant, the restricted stock vested as to 200% of the number of shares granted based on specific performance metrics of the registrant during the period beginning on January 1, 2024 through December 31, 2025. |
| F5 | Represents shares withheld to cover tax withholding obligations in connection with the vesting of the performance-based restricted stock award. |